Biocon Limited announced that the European Commission has granted marketing authorization for Pebrilzo, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union.
The approval makes Biocon's pertuzumab biosimilar the first biosimilar to receive EC marketing authorization under the European Medicines Agency's new tailored clinical approach.
European Approval Secured for Fifth Oncology Biosimilar
The milestone follows a positive CHMP opinion issued on September 17, 2026, and comes after a recent approval of the same biosimilar by the U.S. Food and Drug Administration.
Shreehas Tambe, CEO and Managing Director of Biocon, said the EC approval marks a significant regulatory milestone for the company.
According to Tambe, pertuzumab becomes Biocon's fifth oncology biosimilar approved in both Europe and the United States, strengthening the company's global oncology portfolio and reinforcing its commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.
Molecule and Indications
Biocon's pertuzumab biosimilar is approved as a 420 mg concentrate solution for infusion. The active substance, pertuzumab, is a monoclonal antibody that binds with high affinity and specificity to the human epidermal growth factor receptor 2 (HER2), inhibiting the proliferation of tumour cells that overexpress HER2.
The product is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence. It is also indicated in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.
In addition, the biosimilar is approved for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
The company stated that extensive orthogonal, state-of-the-art structural and functional analytical characterisation, together with comparative clinical pharmacokinetic data, demonstrated that the biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.
Trusted by Leading EPCs & Manufacturers
Find the Latest Pharmaceutical Plant Projects in the European Union
Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information
Request Free Trial → Learn More →
No credit card Up-to-date coverage
Strategic Context for Biocon
The EC authorization aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe, according to Biocon. The company said the milestone strengthens its growing oncology portfolio and its focus on addressing evolving patient and healthcare needs.
Biocon's oncology commitment spans multiple areas of cancer care, including solid tumors such as breast cancer, as well as supportive care addressing chemotherapy-induced neutropenia.
That commitment also extends to bone health, with therapies addressing osteoporosis, treatment-related bone loss, and skeletal complications associated with advanced cancers.
The company said biosimilar pertuzumab further strengthens its portfolio and its ability to support patients across different stages of the cancer care journey and diverse healthcare systems.
Breast Cancer Burden in Europe
Breast cancer remains the most commonly diagnosed cancer among women in Europe. According to 2024 estimates from the European Cancer Information System (ECIS), it is the leading cancer diagnosis among women across the region.
Approximately 15 to 20 percent of invasive breast cancers are characterised by HER2 overexpression or amplification.
Biocon noted that despite significant advances in HER2-targeted treatment, the burden of breast cancer underscores the importance of broad and sustainable access to high-quality treatment options across European healthcare systems.
About Biocon Limited
Biocon Limited, traded on the BSE (532523) and NSE (BIOCON), is a global biopharmaceutical company headquartered in Bengaluru, India, driven by its purpose to provide affordable, life-changing medicines to patients worldwide.
The company addresses healthcare challenges across chronic and non-communicable diseases by offering biosimilars and generics at scale across geographies, focusing on areas of high unmet need, including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health.
To date, Biocon has commercialized 12 biosimilar products and more than 30 generic formulations globally. Its research and development pipeline includes more than 20 biosimilar assets, as well as GLP-1 peptides and other complex generics.
With an integrated lab-to-patient model, the company brings together research and development, manufacturing, and commercial capabilities to ensure a reliable and scalable supply of medicines.
Biocon operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. The company has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year.
One Platform for Every EU Chemical Project That Matters
How do you stay ahead of a project pipeline that spans dozens of countries, regulations, and market dynamics in the chemical sector? Most teams can't, and that's precisely where the competitive gap opens up.
The Global Project Tracking (GPT) platform by Blackridge Research provides a comprehensive overview of the entire chemical sector landscape in Europe, all in one searchable interface. Whether you're focusing on new chemical plant developments, regulatory changes, or market expansions, you gain critical insights ahead of your competitors, ensuring you never miss an opportunity.
From initial project announcements to final completions, every aspect of every monitored chemical sector project is readily accessible, with tender activities, contract awards, and construction milestones continuously updated.
Upcoming Projects
Tender Notices
Contract Awards
Projects Under Construction
Completed Projects
Book a Free Demo today and see how the Global Project Tracking (GPT) platform by Blackridge Research can sharpen your European Union chemical market strategy.
Leave a Comment
We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.
We read every comment and do our best to respond to them all.